Scholar Rock Holding Operating Cash Flow Growth & History (SRRK)
Scholar Rock Holding's operating cash flow was −$300.0M for fiscal 2025.
View full Scholar Rock Holding company overviewScholar Rock Holding annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$300.0M | −$99.1M | — |
| 2024 | 2024-12-31 | −$200.9M | −$55.7M | — |
| 2023 | 2023-12-31 | −$145.2M | −$12.5M | — |
| 2022 | 2022-12-31 | −$132.7M | −$5.9M | — |
| 2021 | 2021-12-31 | −$126.8M | −$66.5M | — |
| 2020 | 2020-12-31 | −$60.3M | $2.8M | — |
| 2019 | 2019-12-31 | −$63.1M | −$87.7M | — |
| 2018 | 2018-12-31 | $24.6M | $46.3M | — |
| 2017 | 2017-12-31 | −$21.7M | — | — |
Scholar Rock Holding quarterly operating cash flow
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$70.3M | $6.6M | — |
| Q1 2026 | 2026-03-31 | −$82.1M | −$3.4M | — |
| Q4 2025 | 2025-12-31 | −$75.5M | −$26.0M | — |
| Q3 2025 | 2025-09-30 | −$68.9M | −$16.5M | — |
| Q2 2025 | 2025-06-30 | −$76.9M | −$27.7M | — |
| Q1 2025 | 2025-03-31 | −$78.7M | −$28.9M | — |
| Q4 2024 | 2024-12-31 | −$49.5M | −$12.2M | — |
| Q3 2024 | 2024-09-30 | −$52.5M | −$20.2M | — |
| Q2 2024 | 2024-06-30 | −$49.2M | −$16.6M | — |
| Q1 2024 | 2024-03-31 | −$49.8M | −$6.7M | — |
| Q4 2023 | 2023-12-31 | −$37.3M | −$8.4M | — |
| Q3 2023 | 2023-09-30 | −$32.3M | −$5.8M | — |
| Q2 2023 | 2023-06-30 | −$32.5M | $2.2M | — |
| Q1 2023 | 2023-03-31 | −$43.1M | −$489,000 | — |
| Q4 2022 | 2022-12-31 | −$28.9M | $3.5M | — |
| Q3 2022 | 2022-09-30 | −$26.5M | $9.5M | — |
| Q2 2022 | 2022-06-30 | −$34.7M | −$2.9M | — |
| Q1 2022 | 2022-03-31 | −$42.6M | −$16.0M | — |
| Q4 2021 | 2021-12-31 | −$32.5M | −$12.8M | — |
| Q3 2021 | 2021-09-30 | −$36.0M | −$12.6M | — |
| Q2 2021 | 2021-06-30 | −$31.8M | −$12.0M | — |
| Q1 2021 | 2021-03-31 | −$26.5M | −$29.2M | — |
| Q4 2020 | 2020-12-31 | −$19.7M | −$3.6M | — |
| Q3 2020 | 2020-09-30 | −$23.4M | −$8.3M | — |
| Q2 2020 | 2020-06-30 | −$19.8M | −$3.4M | — |
| Q1 2020 | 2020-03-31 | $2.6M | $18.2M | — |
| Q4 2019 | 2019-12-31 | −$16.1M | −$71.2M | — |
| Q3 2019 | 2019-09-30 | −$15.1M | −$6.1M | — |
| Q2 2019 | 2019-06-30 | −$16.4M | −$4.8M | — |
| Q1 2019 | 2019-03-31 | −$15.5M | −$5.6M | — |
| Q4 2018 | 2018-12-31 | $55.1M | — | — |
| Q3 2018 | 2018-09-30 | −$9.0M | −$3.3M | — |
| Q2 2018 | 2018-06-30 | −$11.6M | — | — |
| Q1 2018 | 2018-03-31 | −$9.9M | — | — |
| Q3 2017 | 2017-09-30 | −$5.7M | — | — |
Scholar Rock Holding operating cash flow trends
Over the last five fiscal years, Scholar Rock Holding's operating cash flow decreased from −$60.3M to −$300.0M, a change of −$239.8M. The latest reported quarter, Q2 2026, shows −$70.3M.
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Scholar Rock Holding source filings ↗Community posts
Scholar Rock wins FDA approval for muscle-targeted SMA treatment
Scholar Rock ($SRRK) received FDA approval for ISEMBYLD, its apitegromab treatment for spinal muscular atrophy, in patients aged two and older receiving SMN2-targeted therapy. The company plans to begin shipping the medicine within days. Th ...